PPS.http://dx.doi.org/10.3346/jkms.2013.28.11.http://jkms.orgKim H, et al. ?Survival after Progression on GefitinibIn conclusion, resumed TKI use or pemetrexed use in NSCLC patients with acquired resistance to gefitinib is linked to longer PPS and hence merits additional evaluation. These regimens might be great remedy solutions for individuals who develop acquired resistance to gefitinib.11. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8. 12. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, et al. Screening for epidermal development element receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-67. 13. Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, J ne PA, Lynch T, Johnson BE, Miller VA.6-Bromobenzo[cd]indol-2(1H)-one Chemical name Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-smallcell lung cancer. J Clin Oncol 2010; 28: 357-60. 14. Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton K, 1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32. 2. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809-18. 3. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, et al. Efficacy of gefitinib, an inhibitor in the epidermal growth issue receptor tyrosine kinase, in symptomatic sufferers with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-58. four. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, et al. Erlotinib in lung cancer – molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 13344. 5. Paez JG, J ne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500. 6. J ne PA, Johnson BE. Impact of epidermal development factor receptor tyrosine kinase domain mutations around the outcome of patients with non-small cell lung cancer treated with epidermal development aspect receptor tyrosine kinase inhibitors. Clin Cancer Res 2006; 12: 4416s-20s. 7. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al.Formula of 2-Isopropyl-6-nitroaniline Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of your epidermal development factor receptor (WJTOG3405): an open label, randomised phase 3 trial.PMID:24275718 Lancet Oncol 2010; 11: 121-8. 8. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 94757. 9. Jackman DM, Miller VA, Cioffredi LA, Yeap BY, J ne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer.
